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We retrospectively identified 14 elderly patients with a history of partial seizures who received levetiracetam (LEV) monotherapy.
Patients began LEV either as first line therapy (n = 5) or were converted to LEV monotherapy (n = 9) after failing prior
antiepileptic medications (AEDs). Thirteen patients continued on LEV monotherapy for at least 6 months. One patient was lost
to follow-up. Eight patients (61.5%) became seizure free. Four patients who began LEV as a first line therapy became seizure
free, whereas the remaining four patients who converted to LEV after they failed their previous AEDs became seizure free.
Four patients (30.7%) had more than a 50% seizure reduction of seizures. Only one patient had no significant change in seizure
frequency after started on LEV. The total dosages used to control seizures were 500–3000 mg/day, (mean 1839.2 mg/day). LEV
monotherapy can be effective and well tolerated in this group of patients. A prospective, larger, double blind monotherapy study
is needed to confirm this finding.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Advanced age patients ≥60 years of age may have
an increased sensitivity to the effects of AEDs, due
to age-dependent changes in pharmacokinetics and
pharmacodynamics. Pharmacokinetic changes may
include a lower degree of drug binding to plasma
proteins and decreased metabolic and renal drug
clearance1.
Levetiracetam (LEV) has been approved as adjunc-
tive treatment for adults with partial onset seizures2, 3.
LEV has a favorable pharmacokinetic profile that
includes minimal protein binding, lack of hepatic
metabolism, and twice a day dosing4. These features
and others make it ideal for use as monotherapy in el-
derly patients. We wished to evaluate our experience
with LEV as monotherapy in this group of patients to
examine its efficacy and tolerability.
METHODS
We retrospectively reviewed the charts of all of
our elderly patients aged 60 and above with a con-
firmed diagnosis of epilepsy who had two unpro-
voked seizures. Forty-five patients were identified. Of
these, 14 patients were tried on LEV either as first
line therapy or were converted to LEV monother-
apy after failing their prior antiepileptic medications
(AEDs).
We reviewed demographic data, diagnostic evalua-
tion for epilepsy, seizure types, and seizure frequency
prior to and following initiation of LEV monother-
apy. All patients had their LEV dose titrated up to
3000 mg/day or up to seizure freedom. We compared
baseline seizure counts from 3 months prior to initia-
tion of LEV treatment to seizure counts at 6 months
of follow-up after LEV was started and maintained
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as therapy. Seizure frequency was determined using
a seizure diary completed by each patient or their
caregivers, which is standard practice in our clinic.
Adverse events (AEs) while on LEV were also noted
at each clinic visit. This information was kept in
a computerised data system that was maintained
up-to-date.
RESULTS
We identified 14 patients, ages 62–92 years, mean
(66 years) with a history of partial seizures with
and without secondarily generalisation. The duration
of epilepsy ranged from 1 to 39 years (mean 12.6
years, median 2.5). Eight patients were diagnosed
with epilepsy after the age of 60. Five patients be-
gan LEV as first line therapy. Two of these patients
had liver disease and consequently wished to avoid
AEDs that required hepatic metabolism. The remain-
ing three patients chose to start LEV because of its
favorable pharmacokinetic and side-effect profile.
Nine patients were converted to LEV monotherapy
after they failed their initial trials of AEDs, which
included Dilantin, Tegretol, Depakote, and Lamictal
(mean 1.6).
Of the eight newly diagnosed patients, two had AD
and one patient had stroke as a cause of epilepsy.
The remaining six chronic patients had an identifi-
able cause to their seizures: two secondary to head
trauma, two secondary to strokes, and two secondary
to Alzheimer disease (AD).
Of the 14 patients, 13 (93%) of the patients contin-
ued on LEV monotherapy for at least 6 months. One
patient was lost to follow-up. Eight patients (61.5%)
became seizure free. Four patients who began LEV
as monotherapy became seizure free, whereas the re-
maining four patients who began LEV as add-on ther-
apy and remained on LEV as monotherapy became
seizure free.
Two patients (15%) had more than a 50% but less
than 75% seizure reduction and two patients (15%)
had more than a 75% but less than 100% reduc-
tion of seizures. One patient with newly diagnosed
epilepsy (less than 2 years duration) had no sig-
nificant change in her seizure frequency. The total
dosages used to control seizures for all patients were
500–3000 mg/day (mean 1839.2 mg/day). Character-
istics and demographics of our group of patients are
summarised in Table 1.
One patient reported being dizzy within days after
starting LEV but was able to continue on LEV. All pa-
tients were required to have liver function tests, com-
plete blood counts at baseline prior to start LEV, and
at 6 months follow-up. No blood abnormalities were
noted and no other major AEs were reported.
Table 1: Demographics and characteristics of the group.
Variable LEV (n = 14)
Mean age (years) (SD) 66.14 (8.5)
Gender (% male/female) 20/80
Age at epilepsy onset (years) (SD) 52.64 (21.1)
Mean duration of epilepsy (years) (SD) 12.64 (16.98)
Cause of epilepsy (% unknown) 8/14 (57%)
Mean number of previous AEDs (SD) 1.6 (0.89)
Mean seizures frequency (number/month) 2.44
Mean LEV dosages (mg/day) 1928.57
DISCUSSION
This study suggests that LEV monotherapy can be ef-
fective in newly diagnosed elderly epilepsy patients
≥60 years of age who were AED-naive, as well as in
elderly patients with chronic epilepsy. Of the eight pa-
tients with newly diagnosed epilepsy, six patients be-
came seizure free after at least 6 months of follow-up,
while one patient had no significant change in seizure
frequency, and one patient was lost to follow-up. These
findings support the current belief that most older pa-
tients will remain seizure free on AED monotherapy5.
Inadequate seizure control in this group could suggest
poor compliance or progressive disease.
Information on efficacy and tolerability of estab-
lished, as well as new AEDs, is scarce in the el-
derly population. Few randomised controlled trials
have been undertaken in this age group utilising old
and new AEDs6, 7. Previous work utilising LEV as
an add-on therapy for 78 patients ≥65 years of age
have shown complete seizure reduction in 40% of pa-
tients, while 76% achieved more than a 50% reduc-
tion of seizures8. In that study, more than half of the
patients were taking 1000 mg/day. To our knowledge,
this current report is the first one studying the efficacy
and tolerability of LEV as monotherapy in this patient
population. Previous work at this center, as well as
the work of others have demonstrated that LEV can
be effective as monotherapy in newly diagnosed adult
patients as well as in patients with difficult to control
seizures9, 10.
It has been noted that the elderly have generally
increased sensitivity to medications; a factor that may
account for the increased incidence of poor tolerability
and poor compliance. Several factors can influence the
pharmacokinetics and pharmacodynamics of AEDs in
the elderly. Of particular concern is the lowered serum
albumin that frequently occurs in older patients. In
addition, many of these patients take other medication
for various medical conditions that require prolonged
treatment. It is estimated that the average number of
medication among older ambulatory people screened
for undetected medical illnesses is 3.7 medications per
patient11. Of the new AEDs, LEV is believed to be
60 T. M. Alsaadi et al.
free of drug–drug interactions and minimally protein
bound. This suggests that LEV may be an ideal choice
for this elderly group of patients.
The small number of patients studied, as well as the
retrospective nature of this study and the short-term
follow-up, along with lack of randomisation may not
allow us to make firm conclusions. However, our pre-
liminary data suggests that LEV may be an acceptable
choice as monotherapy for the elderly. It is very well
tolerated, with minimum reports of minor side effects.
A prospective, large, double blind study is needed to
confirm this finding.
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